Literature DB >> 21214724

Treatment considerations with aldosterone receptor antagonists.

Domenic A Sica1, John M Flack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21214724      PMCID： PMC8673171          DOI： 10.1111/j.1751-7176.2010.00377.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  29 in total

1.  Low-dose spironolactone in the management of resistant hypertension: a surveillance study.

Authors:  Deirdre A Lane; Sarah Shah; D Gareth Beevers
Journal:  J Hypertens       Date:  2007-04       Impact factor: 4.844

2.  Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?

Authors:  Azra Mahmud; Mohammed Mahgoub; Mary Hall; John Feely
Journal:  Am J Hypertens       Date:  2005-12       Impact factor: 2.689

Review 3.  Aldosterone-receptor antagonism in hypertension.

Authors:  Pieter M Jansen; A H Jan Danser; Ben P Imholz; Anton H van den Meiracker
Journal:  J Hypertens       Date:  2009-04       Impact factor: 4.844

4.  Comparison of a single-dose and twice-a-day spironolactone therapy in mild hypertension.

Authors:  A Ludbrook; M Dynon; F A Mendelsohn; W J Louis
Journal:  Med J Aust       Date:  1980-02-09       Impact factor: 7.738

5.  Effect of spironolactone on blood pressure in subjects with resistant hypertension.

Authors:  Neil Chapman; Joanna Dobson; Sarah Wilson; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Journal:  Hypertension       Date:  2007-02-19       Impact factor: 10.190

6.  Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

Authors:  Myron H Weinberger; Barbara Roniker; Scott L Krause; Robert J Weiss
Journal:  Am J Hypertens       Date:  2002-08       Impact factor: 2.689

7.  Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO.

Authors:  Hari K Parthasarathy; Khamis Alhashmi; Alex D McMahon; Allan D Struthers; Gordon T McInnes; Ian Ford; John M Connell; Thomas M MacDonald
Journal:  J Hypertens       Date:  2010-01       Impact factor: 4.844

8.  The evolution of aldosterone antagonists.

Authors:  Susan M Garthwaite; Ellen G McMahon
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

9.  Efficacy of low-dose spironolactone in subjects with resistant hypertension.

Authors:  Mari Konishi Nishizaka; Mohammad Amin Zaman; David A Calhoun
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

10.  Efficacy of spironolactone therapy in patients with true resistant hypertension.

Authors:  Fabio de Souza; Elizabeth Muxfeldt; Roberto Fiszman; Gil Salles
Journal:  Hypertension       Date:  2009-10-26       Impact factor: 10.190
View more
  3 in total

Review 1.  Key advances in antihypertensive treatment.

Authors:  Ludovit Paulis; Ulrike M Steckelings; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2012-03-20       Impact factor: 32.419

Review 2.  Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.

Authors:  Mohammed I Danjuma; Ipshita Mukherjee; Janine Makaronidis; Serge Osula
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

Review 3.  Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.

Authors:  Thomas Unger; Ludovit Paulis; Domenic A Sica
Journal:  Eur Heart J       Date:  2011-09-27       Impact factor: 29.983
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.